Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.41 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | DUSP22 | Q9NRW4 | 1/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | MAX | P61244 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4127839 | 1.00 | PDE4B (0.42) | PDE4BPDE4DALOX5PTPN22GRIN1 | |
| SCHEMBL4133862 | 0.90 | DUSP22 (0.49) | PDE4BALOX5PTPN22GRIN1GRIN2B | |
| SCHEMBL4133860 | 0.90 | DUSP22 (0.49) | PDE4BALOX5PTPN22GRIN1GRIN2B | |
| SCHEMBL4128685 | 0.88 | PIM1 (0.41) | ALOX5PTPN22DUSP3DUSP22MYC | |
| SCHEMBL4634822 | 0.88 | PIM1 (0.41) | ALOX5PTPN22DUSP3DUSP22MYC | |
| SCHEMBL4132445 | 0.88 | FFAR1 (0.47) | PDE4BALOX5HTTDUSP3DUSP22 | |
| SCHEMBL4132443 | 0.88 | FFAR1 (0.47) | PDE4BALOX5HTTDUSP3DUSP22 | |
| SCHEMBL4122531 | 0.87 | ALOX5 (0.46) | ALOX5PTPN22GRIN1GRIN2BDUSP3 | |
| SCHEMBL4122528 | 0.87 | ALOX5 (0.46) | ALOX5PTPN22GRIN1GRIN2BDUSP3 | |
| SCHEMBL4635275 | 0.86 | ALOX5 (0.42) | ALOX5PTPN22DUSP3DUSP22MYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | claimed |
| EP-1934192-A1 | THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS | Torrent Pharmaceuticals Ltd (IN) | 2008-06-25 | — | — | EP | claimed |
| WO-2007032028-A1 | THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS | TORRENT PHARMACEUTICALS LTD. (IN) | 2007-03-22 | — | — | WO | claimed |
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | disclosed |
| EP-1934192-A1 | THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS | Torrent Pharmaceuticals Ltd (IN) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007032028-A1 | THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS | TORRENT PHARMACEUTICALS LTD. (IN) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | PTPRF, PTPA, PTPRJ | PDE4B 161/4885PDE4D 485/4885ALOX5 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.